Anavex Life Sciences Corp (AVXL)

[georgejjl]

“Obtaining exclusive worldwide rights to this intellectual property is exciting as it is another step in Anavex’s overall strategy to build a broad and leading platform of technology and intellectual property for the development of mixed muscarinic and sigma-1 therapeutics. It also adds to our already dominant position in this field,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “By adding AF710B to our pipeline of Alzheimer’s and neurodegenerative drugs, we have another strong small molecule that comes with a very convincing package of preclinical validation. We look forward to advancing AF710B further into the clinic after the required toxicology studies.”

Under the terms of the agreement, Anavex gains exclusive development and commercialization rights for AF710B worldwide. Anavex has agreed to make an upfront payment and LSRI is eligible to receive milestone payments. LSRI may also receive royalty payments, assuming regulatory approval and commercial launch.

https://www.anavex.com/post/anavex-strengthens-alzheimer-s-pipeline-obtains-exclusive-worldwide-rights-to-intellectual-property

If I remember correctly, the royalty payments may be approximately 6% of revenue from Anavex 3-71 (formerly known as AF710B)

GOD bless,